78 filings
Page 3 of 4
8-K
33h2nsogwhpf
17 Nov 20
Other Events
9:07am
8-K
l224u
17 Nov 20
Three months post-gene therapy, first patient in Gaucher trial shows reductions in the toxic metabolite
7:39am
8-K
lbb7v
5 Nov 20
AVROBIO Reports Third Quarter 2020 Financial Results and Provides Business Update
7:18am
8-K
05tcke3w190 goxqa0
21 Oct 20
AVROBIO Appoints Dr. Gail Farfel to its Board of Directors
8:19am
8-K
fcxvs l1h2apr
6 Oct 20
Regulation FD Disclosure
8:29am
8-K
m94v3
5 Oct 20
AVROBIO Expands Lentiviral Gene Therapy Pipeline with Program for Hunter Syndrome
7:10am
8-K
dmb26igs4s9khuxq
6 Aug 20
AVROBIO Reports Second Quarter 2020 Financial Results and Provides Business Update
7:07am
8-K
hv8h7 fb3boeh5pc8
6 Jul 20
AVROBIO Announces New Patients Dosed in Gaucher Disease and Cystinosis Clinical Trials
7:35am
8-K
s3f1w49 s4q
16 Jun 20
Regulation FD Disclosure
8:24am
8-K
zub3rrn5
9 Jun 20
Submission of Matters to a Vote of Security Holders
4:30pm
8-K
o1t kstkb61
14 May 20
Regulation FD Disclosure
7:05am
8-K
0s5s7p8
13 May 20
Regulation FD Disclosure
7:06am
8-K
srerp3
7 May 20
AVROBIO Reports 1Q 2020 Financial Results and Provides Business Update
7:06am
8-K
1eenhwbp
3 Apr 20
Regulation FD Disclosure
8:01am
8-K
358igltoalqm375
30 Mar 20
Other Events
4:50pm
8-K
5r302id1id
16 Mar 20
AVROBIO Reports Fourth Quarter and Fiscal Year 2019 Financial Results and Provides Business Update
7:11am
8-K
m407u4n
13 Feb 20
AVROBIO Announces Proposed Public Offering of Common Stock
4:14pm
8-K
05u588s8ghg7
10 Feb 20
Other Events
4:09pm
8-K
ol6bxdgx
13 Jan 20
Regulation FD Disclosure
7:01am
8-K
lh2wpyjpbl
7 Nov 19
AVROBIO, Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update
7:05am